Part, Chapter, Paragraph
1 II, 5. 2. 6| countries. Acta Med Scand Suppl 460: 1-392.~Weijenberg MP,
2 II, 5. 2. 7| trends. Int J Epidemiol 18 (suppl):S20–S28.~Thom TJ, Epstein
3 II, 5. 3. 2| oxfordjournals.org/content/vol18/suppl_3/index.dtl.~ ~ ~ ~
4 II, 5. 3. 9| 20th century. Ann Oncol 14 (suppl 5):v128-v149.~ ~ESMO (2006):
5 II, 5. 3. 9| 2007): Summary. Ann Onc 18 (Suppl 3): iii2–iii7.~ ~Micheli
6 II, 5. 3. 9| Eur J Public Health 13(3 Suppl):116-118.~ ~Parkin DM, Bray
7 II, 5. 3. 9| commentary. Ann Oncol 14 (suppl 5):v61-v118.~ ~Stewart BW,
8 II, 5. 4. 8| Res Clin Pract, 2000; 50(Suppl 1):35-47.~ ~K H (1998):
9 II, 5. 5. 1| project. Acta Psychiatr Scand (suppl 420): 21-27.~ ~Alonso J,
10 II, 5. 5. 1| Acta Psychiatr Scand 109 (suppl 420):47-54.~ ~Alonso J,
11 II, 5. 5. 1| ESEMeD). J Clin Psychiatry 68(suppl 2): 3-9.~ ~Berk M, Dodd
12 II, 5. 5. 1| Survey. Br J Psychiatry 168(Suppl. 30):17–30.~ ~Kovess-Masféty
13 II, 5. 5. 1| studies. J Clin Psychiatry 68(Suppl 2):36-41.~ ~L . (2002).
14 II, 5. 5. 3| Europe. Eur J Neurol 12 Suppl 1:1-27.~Andlin-Sobocki P,
15 II, 5. 5. 3| Europe. Eur J Neurol 12 Suppl 1:74-77.~Andrews G, Sandersson
16 II, 5. 5. 3| Clinical Psychiatry 2005, 66 (suppl. 10)~Knapp M, Romeo R, Beecham
17 II, 5. 5. 3| Employment. Epilepsia 44 (suppl 6):49-50.~Barraclough BM (
18 II, 5. 5. 3| a review. Epilepsia 38(suppl 11):S15-S19.~Olafsson E,
19 II, 5. 5. 3| factors. Acta Neurol Scand 91(Suppl 161):71-76.~Boiko AN (1994):
20 II, 5. 5. 3| registers – EDMUS. Ann Neurol 36(suppl):S136–S139.~Confavreux C,
21 II, 5. 5. 3| research. Acta Neurol Scand 183(Suppl):37-40.~Nicoletti A, Lo
22 II, 5. 5. 3| Europe. Eur J Neurol 12 Suppl 1:1-27.~Baldereschi M, Di
23 II, 5. 5. 3| neurologica Scandinavica 42:Suppl 24:21-89.~Bundesamt für
24 II, 5. 5. 3| s disease. Mov Disord 22 Suppl 17:S343-350.~Global Parkinson’
25 II, 5. 5. 3| Europe. Eur J Neurol 12 Suppl 1:68-73.~Logroscino G (2005):
26 II, 5. 7. 7| Am Soc Nephrol 2003;14(7 Suppl 2):S131-S138.~Chen J, Wildman
27 II, 5. 7. 7| for therapy. Kidney Int Suppl 2005 Sep;(98):S25-S29.~Diez
28 II, 5. 7. 7| for the future? Kidney Int Suppl 2004 Nov;(92):S7-10.~Gansevoort
29 II, 5. 7. 7| general population. Kidney Int Suppl 2005 Apr;(94):S28-S35.~Garcia-Lopez
30 II, 5. 7. 7| Dial Transplant 2001;16 Suppl 7:57-60~Lin J, Knight EL,
31 II, 5. 7. 7| J Am Soc Nephrol 2002;13(Suppl 1):S37-S40.~McKenna AM,
32 II, 5. 7. 7| Am J Kidney Dis 2006;47(Suppl 3):S1-S145.~National Kidney
33 II, 5. 7. 7| Am J Kidney Dis 2003;41(suppl 3):S1-S92.~National Kidney
34 II, 5. 7. 7| Am J Kidney Dis 2003;42(Suppl 3):S1-S202.~National Kidney
35 II, 5. 7. 7| Am J Kidney Dis 2004;43(Suppl 1):S1-S290.~Obrador GT,
36 II, 5. 7. 7| EPIRCE study. Kidney Int Suppl 2005 Dec;(99):S16-S19.~Pontoriero
37 II, 5. 9. 7| dust-mite. Indoor Air. 2005;15 Suppl 10:33-9.~ ~European Community
38 II, 5. 9. 7| Pulmonary Medicine 2006, 6(Suppl 1):S2 doi:10.1186/1471-2466-
39 II, 5. 9. 7| Immunol. 2001 Jul;108(1 Suppl):S2-8.~ ~Torén K (2004):
40 II, 5. 12. 7| countries. Addiction 96 Suppl 1:S19-33.~ ~Sauer P, Hansmann
41 II, 8. 2. 1| 50; doi:10.1093/eurpub/13.suppl_1.47~Walsh, P.N., Linehan,
42 II, 9. 1. 1| Gynecol Reprod Biol 2003;111 Suppl 1:S78-87.~ ~Alran S, Sibony
43 II, 9. 1. 1| Gynecol Reprod Biol 2003;111 Suppl 1:S45-52.~ ~Cans C, Guillem
44 II, 9. 1. 1| Nicotine Tob Res 2004;6 Suppl 2:S125-40.~Cnattingius S,
45 II, 9. 1. 1| Gynecol Reprod Biol 2003;111 Suppl 1:S5-S14.~ ~
46 II, 9. 3. 2| Gynecol Reprod Biol 2003;111 Suppl 1:S78-87.~ ~Alran S, Sibony
47 II, 9. 3. 2| Gynecol Reprod Biol 2003;111 Suppl 1:S45-52.~ ~Cans C, Guillem
48 II, 9. 3. 2| Nicotine Tob Res 2004;6 Suppl 2:S125-40.~ ~De Galan-Roosen
49 II, 9. 3. 2| Gynecol Reprod Biol 2003;111 Suppl 1:S5-S14.~ ~ ~
50 III, 10. 1. 3| Alcohol Clin Exp Res 28(5) Suppl:48S-56S.~Blundell JE, King
51 III, 10. 1. 3| Obes Relat Metab Disord 22 Suppl 2:S22-S29.~Bondy SJ (1996):
52 III, 10. 1. 3| Sci Sports Exerc 31(11) Suppl 1:S534-541.~King NA (1998):
53 III, 10. 1. 3| Bull Menninger Clin 58(2 Suppl A):A58-66.~McClelland GH,
54 III, 10. 1. 3| aggression. J Stud Alcohol Suppl 11:53-61.~Miller NS, Giannini
55 III, 10. 1. 3| Obes Relat Metab Disord 23 Suppl 8: S1-S107.~Rehm J, Ashley
56 III, 10. 1. 3| aggression. J Stud Alcohol Suppl 11:78-88.~Thakker KD (1998):
57 III, 10. 1. 3| dual pathway. Acta Paediatr Suppl 404:9-13.~Wood PD (1994):
58 III, 10. 2. 1| review Am J Prev Med Jun;28(5 Suppl):280-7.~ ~Eurobarometer (
59 III, 10. 2. 1| Oral Epidemiol. 2003; 31 Suppl 1:3-23.~ ~Petersen PE, Bourgeois
60 III, 10. 2. 1| Sports and Exercise, 31(11 Suppl.):S526-S533.~ ~Sjöström
61 III, 10. 2. 1| Related Metabolic Disorders 28(Suppl. 1):S71.~ ~Kapantais E,
62 III, 10. 2. 1| health. Obesity Reviews 5(Suppl. 1):4-104.~ ~Lobstein T,
63 III, 10. 2. 1| method. Eur J Clin Nutr 56 Suppl 2: S1-S3.~ ~European Commission (
64 III, 10. 4. 5| Health Perspectives 108 (Suppl. 1):101-112~ ~MNR (2004)
65 IV, 11. 6. 5| Health Affairs Jan-Jun(Suppl Web Exclusives): W5-97-W5-107.~ ~
66 IV, 13. 9 | Europe. Eur J Neurol 12 Suppl 1:1-27.~EPC (Economic Policy
